HealthcareServices

Revenue of the Glomerulonephritis Market Predicted to Achieve $14.66 Billion by 2030, Driven by 4.7% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glomerulonephritis market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Glomerulonephritis Market in 2026, and what figure is it projected to hit by 2030?

The glomerulonephritis market size has experienced consistent expansion in recent years. It is projected to increase from $11.61 billion in 2025 to $12.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.0%. The growth observed in the past period can be linked to the prevalence of autoimmune disorders, the adoption of kidney biopsy, the expansion of nephrology clinics, the availability of immunosuppressive drugs, and the enlargement of diagnostic laboratories.

The glomerulonephritis market is projected to experience sustained expansion over the coming years. By 2030, this market is anticipated to reach $14.66 billion, demonstrating a compound annual growth rate (CAGR) of 4.7%. This forecasted growth is attributable to several factors, including advancements in renal diagnostics, the evolution of precision nephrology, a rise in the prevalence of chronic kidney disease, the broadening of specialty nephrology care, and enhanced treatment adherence. Key trends identified for the forecast period encompass an intensified focus on early diagnosis of kidney disease, the increasing application of immunosuppressive therapies, a growing embrace of biomarker-based testing, the expansion of dialysis support services, and better management of chronic diseases.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

Which Drivers Are Affecting Market Participation In The Glomerulonephritis Market?

The escalating occurrence of kidney ailments is poised to stimulate the expansion of the glomerulonephritis market. Kidney disorders encompass a spectrum of conditions that impact the kidneys’ structure or function, leading to compromised filtration, inefficient waste removal, and fluid imbalance. The increasing prevalence of these disorders is attributed to elements such as an aging demographic, a surge in chronic diseases like diabetes and hypertension, and lifestyle factors. These disorders foster glomerulonephritis by triggering immune system dysregulation, chronic inflammatory responses, or structural damage, thereby impeding renal filtration and function. For example, as reported by Kidney Research UK in June 2023, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population, a figure anticipated to rise to 7.61 million people by 2033. Therefore, the rising prevalence of kidney disorders will propel the growth of the glomerulonephritis market.

What Segment Categories Are Covered In The Glomerulonephritis Market?

The glomerulonephritis market covered in this report is segmented –

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

Which Trends Are Expected To Influence The Glomerulonephritis Market In The Upcoming Years?

Major companies in the glomerulonephritis market are prioritizing the development of advanced non-immunosuppressive treatments to address unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are therapies designed to treat conditions without weakening or suppressing the immune system, thereby preserving immune function. For instance, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, launched FILSPARI (sparsentan), which was approved by the Food and Drug Administration (FDA) for treating IgA nephropathy, a kidney disease. This drug is currently the only non-immunosuppressive treatment demonstrated to significantly slow the decline of kidney function in these patients. FILSPARI’s approval marks a substantial breakthrough in the management of IgA nephropathy, which is identified as the most common type of primary glomerulonephritis. The therapy offers a novel choice for patients who previously had limited options. This approval underscores Travere’s commitment to improving patient outcomes in kidney disease.

Which Leading Companies Dominate The Glomerulonephritis Market Share?

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Glomerulonephritis Market?

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glomerulonephritis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Browse Through More Reports Similar to the Global Glomerulonephritis Market 2026, By The Business Research Company

Diabetic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795